Blueprint Med(BPMC.US)

Last Updated 19:00:00 ET
longbridge loading

Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout

Pharmaceutical Technology·
US
GILD
-0.15%
US
SBIO
+1.84%
US
IHE
+1.29%
Pharmaceutical Technology·
US
GILD
-0.15%
US
SBIO
+1.84%
US
IHE
+1.29%

Galapagos Seeks Strategic Tie-Up With Gilead Around Ouro Medicines Deal and T Cell Engager OM336

Tip Ranks·
US
GLPG
0.00%
US
IBB
+0.68%
US
LABU
+2.48%
Tip Ranks·
US
GLPG
0.00%
US
IBB
+0.68%
US
LABU
+2.48%

Rights to antibody drug from China’s Keymed change hands in US acquisition

SCMP·
US
XBI
+0.81%
US
SBIO
+1.84%
US
IBBQ
+0.82%
SCMP·
US
XBI
+0.81%
US
SBIO
+1.84%
US
IBBQ
+0.82%

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases | GILD Stock News

StockTitan·
DE
GIS
0.00%
US
FBT
+0.69%
StockTitan·
DE
GIS
0.00%
US
FBT
+0.69%

Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis

PharmaTimes·
US
PBE
+0.35%
US
IXJ
+0.67%
US
ALDX
+2.58%
PharmaTimes·
US
PBE
+0.35%
US
IXJ
+0.67%
US
ALDX
+2.58%

Four-year data shows long-term benefit and safety of AYVAKIT in Indolent Systemic Mastocytosis. 12 presentations at AAAAI Meeting.

Unusual Whales·
US
IBBQ
+0.82%
US
IBB
+0.68%
US
BBH
+0.64%
Unusual Whales·
US
IBBQ
+0.82%
US
IBB
+0.68%
US
BBH
+0.64%

09:45 ETBlueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis

prnewswire·
US
BIB
+1.41%
US
IXJ
+0.67%
US
PBE
+0.35%
prnewswire·
US
BIB
+1.41%
US
IXJ
+0.67%
US
PBE
+0.35%

BeOne Medicines Earnings Report: Q4 Overview

benzinga_article·
US
IXJ
+0.67%
US
BIB
+1.41%
US
XBI
+0.81%
benzinga_article·
US
IXJ
+0.67%
US
BIB
+1.41%
US
XBI
+0.81%
© 2026 Longbridge｜Disclaimer